Rationalisation of the purification process for a phage active pharmaceutical ingredient

被引:2
|
作者
Lapras, B. [1 ,2 ]
Marchand, C. [1 ,3 ]
Merienne, C. [1 ]
Medina, M. [3 ,4 ]
Kolenda, C. [3 ,4 ]
Laurent, F. [3 ]
Pirot, F. [1 ,2 ]
机构
[1] Hop Edouard Herriot, Hosp Civils Lyon, FRIPHARM, Pharm Dept, F-69437 Lyon, France
[2] Claude Bernard Lyon 1 Univ, CNRS, UMR 5305, Inst Biol & Chim Prot IBCP,French Natl Ctr Sci Res, F-69007 Lyon, France
[3] Croix Rousse Hosp, Hosp Civils Lyon, French Natl Reference Ctr Staphylococci, Bacteriol Dept, F-69317 Lyon, France
[4] Claude Bernard Lyon 1 Univ, CNRS, INSERM, UMR 5308,U1111,Ctr Int Rech Infectiol CIRI, F-69365 Lyon, France
关键词
Bacteriophages; Phage active pharmaceutical ingredient; Phage purification; Phage lysate impurities; Separation unit operations; Rationalisation of process development; AFFECTING ENDOTOXIN REMOVAL; VIRUS PURIFICATION; AQUEOUS-SOLUTIONS; BACTERIOPHAGE; THERAPY; RNA; ELECTROKINETICS; ULTRAFILTRATION; CHROMATOGRAPHY; AGGREGATION;
D O I
10.1016/j.ejpb.2024.114438
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The resurgence of phage therapy, once abandoned in the early 20th century in part due to issues related to the purification process and stability, is spurred by the global threat of antibiotic resistance. Engineering advances have enabled more precise separation unit operations, improving overall purification efficiency. The present review discusses the physicochemical properties of impurities commonly found in a phage lysate, e.g., contaminants, phage-related impurities, and propagation-related impurities. Differences in phages and bacterial impurities properties are leveraged to elaborate a four-step phage purification process: clarification, capture and concentration, subsequent purification and polishing. Ultimately, a framework for rationalising the development of a purification process is proposed, considering three operational characteristics, i.e., scalability, transferability to various phages and duration. This guide facilitates the preselection of a sequence of unit operations, which can then be confronted with the expected impurities to validate the theoretical capacity of the process to purify the phage lysate.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] A Continuous Rotary Filtration for the Separation and Purification of an Active Pharmaceutical Ingredient
    Wu, Wei
    Sayin, Ridade
    Shvedova, Khrystyna
    Born, Stephen C.
    Testa, Christopher J.
    Yeole, Shalabh S.
    Censullo, Alexander S.
    Srivastava, Anup Kumar
    Ramnath, Anjana
    Hu, Chuntian
    Takizawa, Bayan
    O'Connor, Thomas F.
    Yang, Xiaochuan Benjamin
    Ramanujam, Sukumar
    Mascia, Salvatore
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2023, 28 (05) : 1618 - 1631
  • [2] The use of ultrasound in the crystallization process of an active pharmaceutical ingredient
    Belca, Lucija Majal
    Rucigaj, Ales
    Teslic, Dusan
    Krajnc, Matjaz
    ULTRASONICS SONOCHEMISTRY, 2019, 58
  • [3] Safer Solvents for Active Pharmaceutical Ingredient Purification Using Column Chromatography
    Ayafor, Christian
    Burton, Toren
    George, Nathaniel
    Morose, Gregory
    Wong, Hsi-Wu
    ACS ENVIRONMENTAL AU, 2024, 4 (05): : 236 - 247
  • [4] Polybenzimidazole for Active Pharmaceutical Ingredient Purification: The Mometasone Furoate Case Study
    Ferreira, Flavio Alves
    Esteves, Teresa
    Carrasco, Marta P.
    Bandarra, Joao
    Afonso, Carlos A. M.
    Ferreira, Frederico Castelo
    INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH, 2019, 58 (24) : 10524 - 10532
  • [5] Formulation of tablets containing an 'in-process' amorphized active pharmaceutical ingredient
    Jojart-Laczkovich, Orsolya
    Szabo-Revesz, Piroska
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2011, 37 (11) : 1272 - 1281
  • [6] Environmental sustainability assessment of the manufacturing process of a biological active pharmaceutical ingredient
    Gamiz, Ana Gabriela Renteria
    De Soete, Wouter
    Heirman, Bert
    Dahlin, Philip
    De Meester, Steven
    Dewulf, Jo
    JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY, 2019, 94 (06) : 1937 - 1944
  • [7] Isolation and characterization of process related impurities in anastrozole active pharmaceutical ingredient
    Hiriyanna, S. G.
    Basavaiah, K.
    JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY, 2008, 19 (03) : 397 - 404
  • [8] Environmental sustainability assessment of a biological active pharmaceutical ingredient manufacturing process
    Gamiz, Ana Gabriela Renteria
    De Soete, Wouter
    Heirman, Bert
    Dahlin, Philip
    De Meester, Steven
    Dewulf, Jo
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [9] Validation of process intermediate storage for the production of active pharmaceutical ingredient.
    Seely, R
    Luscher, M
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 216 : U256 - U256
  • [10] ISOLATION AND CHARACTERIZATION OF PROCESS RELATED IMPURITY IN CEFUROXIME ACTIVE PHARMACEUTICAL INGREDIENT
    Pathi, P. Janaki
    Raju, N. Appala
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 2 (04): : 790 - 795